Posted by Michael Wonder on 19 Dec 2024
LIB Therapeutics submits a biologic license application to FDA for lerodalcibep for the treatment of adults with elevated LDL-cholesterol
16 December 2024 - Lerodalcibep is a novel, adnectin based, small protein binding, third generation PCSK9 inhibitor.
LIB Therapeutics announced the submission of a biologics license application to the US FDA seeking approval of lerodalcibep to reduce low-density lipoprotein cholesterol for the treatment of patients with atherosclerotic cardiovascular disease (ASCVD), or very high or high risk of ASCVD, and primary hyperlipidaemia, including heterozygous and homozygous familial hypercholesterolaemia.
